Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABTECT-1 induction study of obefazimod in moderately to severely active ulcerative colitis
2022-500535-36-01Phase 3Completed
- Sponsor
- Abivax
- Start
- May 2023
- Modality
- Small Molecules
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in autoimmune colitis comparing Obefazimod with Placebo (2 arms). Primary endpoints: Endoscopic improvement at week 8 and Symptomatic remission at week 8. Started May 2023; status: completed.
02
Drugs
obefazimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2022-500535-36-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500535-36-01.